News

NeedleSmart PRO Receives FDA Approval

Published on: 12/04/2021

NeedleSmart PRO Receives FDA Approval
Covid-19
Member News

The award-winning NeedleSmart PRO needle destruction device has achieved FDA approval as a Class II medical device.

Merseyside Based NeedleSmart Ltd is the FIRST UK company to achieve FDA 510(k) approval (Class II for Sharps Needle Destruction Device (NDD).

The innovative NeedleSmart PRO device heats a sharp, contaminated hypodermic needle to 1,300, then compresses the molten metal into a smooth ball at the end of the syringe, removing the danger of needlestick injury and infection in just 6 seconds.

NeedleSmart’s patented technology is engineered in the UK, with offices in Knowsley, Merseyside (UK), and recently opened Pittsburgh, Pennsylvania (USA).

The NeedleSmart PRO will be used in clinical environments including hospitals and GP surgeries, and will be used in digital vaccination programmes and immunisations based in the North West.

The device offers many benefits

  • Reduction of needlestick injuries (NSI) and associated costs both emotional and financial.
  • Sustainability approx. 25% reduction in sharps bin requirement, leading to less waste, and contributing to the overall carbon footprint in the medical sector.
  • Potential introduction of clinisafe bag/box as no longer a sharp.
  • Along with associated software, the device will be used to digitalise vaccination data seamlessly, securely and safely.

Merseyside based NeedleSmart CEO Cliff Kirby added: “I am absolutely thrilled that the NeedleSmart PRO has received FDA approval. Knowing we are the first UK Company to achieve this is a fantastic achievement and pays testament to the product and expertise of our team, and we are looking forward new distribution partnerships in the USA.”

NeedleSmart is a smart med-tech business focused on better health results including safety, clinical process efficiency, cost management, and digitisation of clinical events, whilst improving sustainability. FDA approval marks a milestone in NeedleSmart’s geographic expansion to serve the North American market.

For more information & images please contact:

julie@needlesmart.com

+44 (0)7850630004

T: +44 (0)151 315 0500 (UK)

T: +1 (717) 8561296 (USA)

needlesmart.com

digitalvaccination.com

NEWS​

Related News

Health innovators eye fast-track growth as Leeds transforms historic medical school

16 May 2025
Innovation in healthcare is switching to the fast lane in Leeds as partners shape a globally-leading approach to supporting businesses set to occupy t...

Global Cancer Ecosystem launched to tackle health inequalities worldwide

15 May 2025

BRAINTEASER Legacy: Data, tools and knowledge for advancing future research in digital health for Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS)

14 May 2025
BRAINTEASER Final event – Tuesday 3rd June 2025 – @ENCALS 2025 Meeting

ATRIDE Launches the Next-Gen “Holter for the Lungs” At Web Summit Vancouver 2025

14 May 2025
Atride lung shirt is part of the larger EU funded Digilung project lead by Tehnopol, partners Atride, MoveUP, Cognuse, VUB. The project is highly rele...

Open call of 40k for up to 6-Month VR/AR Co-Creation with Leading European SMEs

13 May 2025
The VR Health Champions project, coordinated by Instituto Pedro Nunes (IPN), has launched an Open Call offering up to €40,000 to SMEs developing innov...

Toronto’s new innovation studio highlights aging-in-place solutions

13 May 2025
Located in the heart of downtown Toronto, the AGE-WELL Innovation Studio is your gateway to the future of aging and care. Whether you’re a tech compan...

Become a member

Join ECHAlliance to amplify your organisation’s message, grow your networks, connect with innovators and collaborate globally.
 
First name *
Last Name *
Email Address *
Country *
Position *
First name *
Last Name *
Email Address *
Country *
Position *